Worth reading
45Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Conditional
How definitive the wording is.Who is moving to which position
Resolved 10 November 2026Incoming appointee
12 itemsScheduled Appointment DateNoevir Holdings Co.,Ltd.: effective 9 December 2026, subject to formal approval at the 16th Annual General Meeting of Shareholders and subsequent meetings of the Board of Directors and Audit & Supervisory Board. 株式会社ノエビア and 常盤薬品工業株式会社: effective 25 November 2026, subject to formal approval at each company's annual general meeting of shareholders and subsequent Board of Directors meetings.
Okura Ken (大倉健)
Previous positionManaging Director
New positionRepresentative Director and Executive Vice President
Ayukawa Kazuya (鮎川和也)
Previous positionExecutive Officer, Head of Corporate Planning, Public Relations and IR Divisions
New positionManaging Director
Watanabe Yoshiki (渡邊芳樹)
Previous positionNot disclosed
New positionOutside Audit & Supervisory Board Members
Baba Junya (馬場淳也)
Previous positionGeneral Manager of the Accounting Department
New positionExecutive Officer, Head of Accounting Division
Uranaka Chiharu (浦中千春)
Previous positionManager, Corporate Planning Department
New positionGeneral Manager of the Corporate Planning Department
Miyoshi Takahiro (三好崇博)
Previous positionManager, Kobe Office, Human Resources Department
New positionHead of Human Resources Department
Sugimasa Sunao (杉政素直)
Previous positionDirector, Head of East Asia Business Division and Market Development Division
New positionRepresentative Director and Executive Vice President
Seki Taizo (関泰三)
Previous positionDirector, CTO, responsible for Product Planning, Plant Materials Development, New Business Development, Satellite Research Institute and Industry-Academia Collaboration
New positionExecutive Managing Director and CTO
Miyaji Nobuyuki (宮地伸幸)
Previous positionDirector, General Manager of Group Research and Development Division
New positionDirector, Head of Group Research and Development Division
Kanda Hideyuki (神田秀之)
Previous positionDirector, Head of Pharmaceutical and Food Business Division
New positionRepresentative Director and Executive Vice President
Kurosawa Nobuyuki (黒沢信之)
Previous positionManager, Healthcare Sales Department, Pharmaceutical and Food Business Division (Sales Promotion)
New positionDirector, Head of Pharmaceutical and Food Business Division
Morimoto Mitsuo (森本光雄)
Previous positionGeneral Manager, Human Resources Department, 株式会社ノエビアホールディングス
New positionDirector, Head of Human Resources and General Affairs Division
Date of birthOkura Ken (大倉健): 24 July 1995. Others: Not disclosed.
Year joined the companyOkura Ken (大倉健): 2021. Others: Not disclosed.
Number of shares heldOkura Ken (大倉健): 10,000 shares (record date: Not disclosed). Others: Not disclosed.
Because the names and counts do not correspond, they are shown as reported without linking the counts to individual names.Departing officer
7 itemsDate of departureFor Koyama Takashi (小山隆) and Sugimoto Kazuya (杉本和也) of Noevir Holdings Co.,Ltd., at the conclusion of the 16th Annual General Meeting of Shareholders scheduled for 9 December 2026. For Kaida Yasuo (海田安夫) of 株式会社ノエビア and Nakano Masataka (中野正隆) and Nakata Kazuki (中田和樹) of 常盤薬品工業株式会社, effective 25 November 2026.
Yoshida Kazuyuki (吉田一幸)Next role stated
Former PositionRepresentative Director and Executive Vice President
New positionFull-time Audit & Supervisory Board Member
Koyama Takashi (小山隆)Next role stated
Former PositionFull-time Audit & Supervisory Board Member
New positionRetirement
Sugimoto Kazuya (杉本和也)Next role stated
Former PositionOutside Audit & Supervisory Board Members
New positionRetirement
Kaida Yasuo (海田安夫)Next role stated
Former PositionChairman of the Board
New positionRetirement
Nakano Masataka (中野正隆)Next role stated
Former PositionChairman of the Board
New positionRetirement
Nakata Kazuki (中田和樹)Next role stated
Former PositionDirector, Head of Human Resources and General Affairs Division
New positionRetirement
Hanyu Mitsuyoshi (羽生光嘉)Next role stated
Former PositionExecutive Officer, Head of Accounting Division
New positionRetirement
“Next role stated” means the document names the position the person holds after stepping down. It does not necessarily mean they are leaving the company.
Reason for departure
It is stated that Yoshida Kazuyuki (吉田一幸) will retire as a director and is scheduled to become a full-time audit & supervisory board member. Other reasons for retirement: Not disclosed.
Whether the incumbent will remain in office (whether they will retain their position)
Yoshida Kazuyuki (吉田一幸) will remain as a full-time audit & supervisory board member. Ayukawa Kazuya (鮎川和也) will retire as an executive officer but is scheduled to become a Senior Managing Director. The other retiring officers will not remain on the Board of Directors.
Directors after the change13Number
Shareholders’ meeting approvalRequired. The matter is scheduled to be submitted to the 16th Annual General Meeting of Shareholders of Noevir Holdings Co.,Ltd., scheduled for 9 December 2026, and to the respective annual general meetings of shareholders of 株式会社ノエビア and 常盤薬品工業株式会社, scheduled for 25 November 2026. Proposal title: Not disclosed.
Reason for change
Strengthening the management structure
| Item | Details |
|---|---|
| Resolution date | 10 November 2026 |
| Scheduled Appointment Date | Noevir Holdings Co.,Ltd.: effective 9 December 2026, subject to formal approval at the 16th Annual General Meeting of Shareholders and subsequent meetings of the Board of Directors and Audit & Supervisory Board. 株式会社ノエビア and 常盤薬品工業株式会社: effective 25 November 2026, subject to formal approval at each company's annual general meeting of shareholders and subsequent Board of Directors meetings. |
| Date of departure | For Koyama Takashi (小山隆) and Sugimoto Kazuya (杉本和也) of Noevir Holdings Co.,Ltd., at the conclusion of the 16th Annual General Meeting of Shareholders scheduled for 9 December 2026. For Kaida Yasuo (海田安夫) of 株式会社ノエビア and Nakano Masataka (中野正隆) and Nakata Kazuki (中田和樹) of 常盤薬品工業株式会社, effective 25 November 2026. |
| Name of appointee | Okura Ken (大倉健), Ayukawa Kazuya (鮎川和也), Watanabe Yoshiki (渡邊芳樹), Baba Junya (馬場淳也), Uranaka Chiharu (浦中千春), Miyoshi Takahiro (三好崇博), Sugimasa Sunao (杉政素直), Seki Taizo (関泰三), Miyaji Nobuyuki (宮地伸幸), Kanda Hideyuki (神田秀之), Kurosawa Nobuyuki (黒沢信之), Morimoto Mitsuo (森本光雄) |
| Appointee's new position | Representative Director and Executive Vice President, Managing Director, Outside Audit & Supervisory Board Members, Executive Officer, Head of Accounting Division, General Manager of the Corporate Planning Department, Head of Human Resources Department, Representative Director and Executive Vice President, Executive Managing Director and CTO, Director, Head of Group Research and Development Division, Representative Director and Executive Vice President, Director, Head of Pharmaceutical and Food Business Division, Director, Head of Human Resources and General Affairs Division |
| Appointee's previous position | Managing Director, Executive Officer, Head of Corporate Planning, Public Relations and IR Divisions, Not disclosed, General Manager of the Accounting Department, Manager, Corporate Planning Department, Manager, Kobe Office, Human Resources Department, Director, Head of East Asia Business Division and Market Development Division, Director, CTO, responsible for Product Planning, Plant Materials Development, New Business Development, Satellite Research Institute and Industry-Academia Collaboration, Director, General Manager of Group Research and Development Division, Director, Head of Pharmaceutical and Food Business Division, Manager, Healthcare Sales Department, Pharmaceutical and Food Business Division (Sales Promotion), General Manager, Human Resources Department, 株式会社ノエビアホールディングス |
| Appointee's date of birth | Okura Ken (大倉健): 24 July 1995. Others: Not disclosed. |
| Year the appointee joined the Company | Okura Ken (大倉健): 2021. Others: Not disclosed. |
| Number of shares held by the appointee | Okura Ken (大倉健): 10,000 shares (record date: Not disclosed). Others: Not disclosed. |
| Name of departing officer | Yoshida Kazuyuki (吉田一幸), Koyama Takashi (小山隆), Sugimoto Kazuya (杉本和也), Kaida Yasuo (海田安夫), Nakano Masataka (中野正隆), Nakata Kazuki (中田和樹), Hanyu Mitsuyoshi (羽生光嘉) |
| Former position of departing officer | Representative Director and Executive Vice President, Full-time Audit & Supervisory Board Member, Outside Audit & Supervisory Board Members, Chairman of the Board, Chairman of the Board, Director, Head of Human Resources and General Affairs Division, Executive Officer, Head of Accounting Division |
| New position of departing officer | Full-time Audit & Supervisory Board Member, Retirement, Retirement, Retirement, Retirement, Retirement, Retirement |
| Reason for departure | It is stated that Yoshida Kazuyuki (吉田一幸) will retire as a director and is scheduled to become a full-time audit & supervisory board member. Other reasons for retirement: Not disclosed. |
| Whether the incumbent will remain in office | Yoshida Kazuyuki (吉田一幸) will remain as a full-time audit & supervisory board member. Ayukawa Kazuya (鮎川和也) will retire as an executive officer but is scheduled to become a Senior Managing Director. The other retiring officers will not remain on the Board of Directors. |
| Reason for change | Strengthening the management structure |
| Number of directors after the change | 13, including 7 outside directors (calculated from the list of directors of 株式会社ノエビアホールディングス) |
| Subject to Approval by the General Meeting of Shareholders | Required. The matter is scheduled to be submitted to the 16th Annual General Meeting of Shareholders of Noevir Holdings Co.,Ltd., scheduled for 9 December 2026, and to the respective annual general meetings of shareholders of 株式会社ノエビア and 常盤薬品工業株式会社, scheduled for 25 November 2026. Proposal title: Not disclosed. |
Items this document does not state (4)
Reasons for appointmentFiling as an independent officerDetails of organizational changesChange in Corporate Governance Structure
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The stated reason for the change in representative directors at Noevir Holdings Co.,Ltd. is to "strengthen the management structure." No individual reasons are provided for the other changes.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.